Thiazides
Thiazide diuretics are commonly used to reduce the risk of calcium stone recurrence. Common drugs and doses are listed in Table 1 5 . Thiazides exert their effect by reducing urinary calcium excretion, thereby reducing hypercalciuria. Thiazides can be effective in both normocalciuric and hypercalciuric patients. The beneficial effects have been confirmed in several studies 6, 7 over the last 55 years and are summarized in the recent AUA guideline on medical management of kidney stones 5 . Thiazides directly stimulate calcium resorption in the distal nephron while reducing the 3 extracellular fluid compartment. The hypocalciuric effect only takes 2-3 days to be established and is limited to thiazide types of diuretics only. It does not extend to other diuretic classes such as loop or potassium-sparing diuretics 8 . Significantly, thiazides can induce hypocitriuria due to hypokalemia and resultant intracellular acidosis. Potassium supplementation (in potassium chloride or potassium citrate form) will correct the hypocitriuria. Since citrate is a renal stone inhibitor, low citrate levels can contribute to stone formation 9 . 37 .5mg / 25mg, once daily While generally well tolerated at low doses, the potential for side effects with thiazides is present. In some studies the side effects are significant enough to stop treatment in 1:6 patients.
In the majority of cases; however, they do improve with time 13, 8 . The most common side effects are dizziness (due to postural hypotension), weakness and fatigue. Other potential side effects include thirst, polyuria, muscle cramps, reversible erectile dysfunction, nausea, vomiting, gastric irritation, diarrhea or constipation, rashes, skin reactions, purpura and blood dyscrasias including thrombocytopenia. Uncommonly, precipitation of gout or diabetes can occur; very rarely pancreatitis and hepatic encephalopathy have been reported 14 . Gout and diabetes precipitation is likely due to disturbances of serum uric acid and glucose levels that have been described with thiazide administration 14 . It is essential to obtain serum potassium measurement when starting thiazide treatment as hypokalemia can occur (due to indirect stimulation of potassium excretion 15 ). This is particularly true in the context of dehydration e.g. vomiting and diarrhea.
Serial serum potassium levels should be checked at regular intervals. It is recommended that concomitant potassium supplementation be administered whenever a thiazide is commenced.
Thiazide use requires caution in renal or liver failure and elderly patients. Mild hypercalcemia is not uncommon. Occasionally administration of a thiazide can unmask primary hyperparathyroidism 8 . Finally, there are several important drug interactions detailed in table 2. 
Urinary alkalinizers
Urinary alkalinizers such as potassium citrate can be used in patients with hypocitriuria. There is a range of doses and formulations available, from tablets (UROCIT®-K Mission Pharmacal Company) and liquids to effervescent drinks 27 . Several formulations are detailed in Table 3 . A more extensive list is available in the Appendix. 
Xanthine oxidase inhibitors
These drugs are commonly used in patients with hyperuricosuria and either uric acid or calcium stones. Uric acid stones account for approximately 9% of renal calculi in the USA 38 .
Furthermore, monosodium urate or uric acid crystals can act as seed crystals for calcium oxalate or adsorb normally occurring inhibitors of calcium oxalate crystallization 39 . It is important to note that the majority of patients with uric acid calculi have low urinary pH and normal urinary 9 uric acid levels 40, 41 . Allopurinol is a xanthine oxidase inhibitor that reduces both serum and urinary uric acid levels. It was first noted as part of the drug discovery program at Burroughs
Wellcome that started in 1940s and culminated in a 1988 Nobel Prize in Physiology and
Medicine. Although generally well tolerated, the most common adverse effects of allopurinol are gastrointestinal distress, hypersensitivity reactions, hepatotoxicity and skin rash 42, 43 . Minor hypersensitivity reactions to allopurinol, including pruritus and dermatitis, occur in approximately 2% of patients 44 . More serious adverse events associated with allopurinol include fever, toxic epidermal necrolysis, alopecia, bone marrow suppression, hepatitis, and vasculitis 43 .
Severe allopurinol-induced toxic effects are rare but can be life-threatening. A dose dependent allopurinol hypersensitivity syndrome is associated with a mortality rate of approximately 20% 45 .
Several drug interactions can also occur. Increased toxicity with thiazide diuretics has been noted (patients who are already taking thiazides for hypercalciuria are at a particular risk) and renal and hepatic function monitoring is required 46 .
Febuxostat is a new type of xanthine oxidase inhibitor. It is preferred in renal impairment as it is hepatically cleared 47 . A recent 2013 trial showed that febuxostat significantly lowered 24-hour urinary acid excretion in patients with calcium stones, compared to allopurinol. There was no change in stone size or number, although the study was only six months in duration 48 . Adverse reactions occurring in at least 1% of Febuxostat-treated patients, and at least 0.5% greater than placebo, are: liver function abnormalities, nausea, arthralgia, and rash 49 . Trials of febuxostat for uric acid and calcium calculi prevention are still awaited.
Treatments for cystinuria
Cystinuria is an inherited autosomal recessive condition, due to a defect in intestinal and renal tubular transport of dibasic amino acids, including cystine 50 . As a result of high urinary cystine levels and poor solubility of cystine these patients form multiple stones, often from an early age.
Initial therapy involves hydration to reduce cystine concentration and reduced oral intake of sodium and protein. Urinary alkalinization is the next step, aiming for pH >7 51 since higher urinary pH increases solubility of cystine 52 . Potassium citrate, as discussed above, is frequently utilized. If these simple measures are inadequate, additional medications are used.
Tiopronin (Thiola ® Mission Pharmacal Company)
Tiopronin is the active reducing agent that undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of Thiola-cysteine 53 . This mixed disulfide is far more soluble than cystine, thereby reducing pure cystine excretion and stone formation. The drug is only available in a 100mg tablet form. Exact dose is dependent on the desired reduction in the urinary cystine excretion. Urinary cystine concentrations are monitored with 24-hour urine testing, so that dose adjustments can be made. Typically, the urinary cystine concentration target is < 300mg/L (cystine solubility limit) to be maximally effective 54 . An average dose in the study of cystinuria patients was approximately 1100mg/day. Tiopronin has fewer side effects than d-penicillamine, a drug also used in cystinuria treatment. Nevertheless, both drugs have significant side effects with 30% of patients needing to stop treatment in one study 55 
D-penicillamine
D-penicillamine acts similar to tiopronin by forming penicillamine-cysteine disulfide that has higher solubility than cystine. Since the side effects are more significant, it is usually reserved as a second-line option. Significant hematological side effects including leukopenia, thrombocytopenia, pancytopenia, aplastic anemia and agranulocytosis have been reported, even leading to fatalities 56 . Proteinuria and hematuria can also develop, progressing to nephrotic syndrome. Hemoptysis and pulmonary infiltrates can also occur. Skin rashes and pemphigus occur in a small number of patients as does myasthenic syndrome. Myasthenic syndrome is characterized by progressive, and typically symmetric, muscle weakness. With D-penicillamine, symptoms usually start 4 to 9 months after initiation of treatment 57 . The symptoms are generally mild and may be limited to extra ocular muscles. Close monitoring of hematological, renal and hepatic parameters is mandatory, initially with twice-weekly tests and clinical examination.
Typical dose starts with 250mg/day and is increased to 500mg qid as required to reduce urinary cystine concentration.
Captopril
Captopril is an ACE inhibitor that contains thiol compounds. There are literature reports of its use in cystinuria 58, 59 . However other studies have failed to confirm effectiveness 60, 61 . As a result it is not routinely used in the treatment of cystinuria patients unless there is the presence of concomitant hypertension. 
Acetohydroxamic acid (AHA)
Struvite stones form as a result of urinary tract infection with urease-splitting organisms,
including Proteus, Pseudomonas and Klebseilla (Table 4 ). The hydrolysis of urea by bacterial urease enzyme increases urinary pH and ammonia levels, with consequent stone formation 62 . 
Drugs used in managing stone symptoms
Acute renal colic is considered to be one of the most excruciatingly painful medical conditions.
A range of analgesia options is available to control acute symptoms. As always, full medical history, examination and appropriate tests are conducted before drugs are prescribed. In particular, renal function can be affected by renal calculi causing obstruction. Significant renal impairment will preclude the use of several analgesics.
Acetaminophen
Acetaminophen is one of the most commonly prescribed analgesics around the world. It has an excellent safety profile. Despite its popularity and use for over 100 years, the mechanism of action is still not fully elucidated. It is thought to have a weak cyclooxygenase inhibitor action 67 .
Acetaminophen has potent anti-pyretic and analgesic actions, despite very weak antiinflammatory activity. It is used as part of the acute management of renal colic. In randomized trials intravenous acetaminophen was as effective as intravenous morphine in relieving acute renal colic pain 68, 69 . As for any drug, there is a small risk of hypersensitivity reaction. High doses >4000mg/24 hours or together with high alcohol intake can cause severe liver damage 70 .
Caution is required in patients with liver or kidney impairment. Thrombocytopenia and hepatic dysfunction (at recommended doses) have been reported very rarely (<1/10,000 patients) 71 .
Immediate medical attention is warranted in the event of an overdose due to risk of permanent liver injury, and may require administration of N-Acetyl-Cysteine 72 .
Cyclooxygenase inhibitors
Cyclooxygenase (COX) enzyme produces prostaglandins. These are mediators of multitude of bodily functions, from physiological, such as gastric protection, platelet and renal function, to pathological, such as fever, pain and inflammation 73 . In particular, PGE2 and prostacyclin are the main inflammatory mediators. Aspirin, diclofenac, ketorolac and similar non-steroidal antiinflammatory drugs (NSAIDs) inhibit cyclooxygenase prostaglandin synthesis and therefore have anti-inflammatory, antipyretic and analgesic effects. These are some of the most commonly used drugs for management of renal colic. In a 2004 systematic review of 20 trials, 1613 patients
given NSAIDs for renal colic achieved greater reductions in pain scores, were less likely to require rescue analgesia or develop vomiting than patients given opioids 74 . In a Cochrane review of 5734 patients from 2015, NSAIDs were again shown to be effective in acute renal colic 75 .
However, these powerful drugs are not without problems. 
Ketorolac
Ketorolac tromethamine is one of the most commonly used NSAID drugs for the treatment of renal colic. In addition to inhibiting prostaglandin synthesis, it may act centrally to diminish perception of pain and reduce ureteric musculature activity 82 . It is typically given in IV or IM form. Tablets (only as continuation of IV form) are also available. Ketorolac has been shown to be more effective than meperidine (narcotic analgesic) in renal colic 83 . Ketorolac carries a boxed FDA warning with total combined duration of oral and injectable use not to exceed 5 days 84 .
Ketorolac side effects are representative of NSAID class in general, including GI bleeding and ulceration, increased risk of cardiovascular thrombotic events, MI and stroke. It should not be used prior to any major surgery, in patients at risk of renal impairment, or in patients >70 years of age. Prolonged bleeding time and coagulopathic effects are noted as with the rest of the NSAID medications. Common adverse reactions include nausea, dyspepsia, abdominal pain, dizziness and drowsiness.
COX-2 inhibitors
A newer class of drugs, COX-2 inhibitors, acts by suppressing inflammatory mediators produced specifically by COX-2 enzyme. COX-1 enzyme has protective physiological functions, such as anti-thrombogenic and cytoprotective effects. COX-2 enzyme is primarily expressed in response to inflammation or other pathological event 73 . Hence, specific COX-2 inhibitors such as 
Opioid analgesics
Opiods are a large class of analgesics, including diverse drugs such as morphine, hydrocodone, oxycodone, fentanyl, codeine and methadone. Opiods are available in oral, intramuscular and intravenous formulations. The earliest opioids were derived from the seeds of poppy plants.
Opioid drugs are typically reserved for more severe pain conditions, when alternative medications are ineffective. Opioids mimic the actions of endogenous opioid peptides by interacting with mu, delta or kappa opioid receptors in the central nervous system. They also decrease intracellular cAMP which modulates the release of nociceptive neurotransmitters (e.g. substance P) 88 . Opioids have been shown in systematic review to be effective in management of renal colic (albeit less effective than NSAIDS) 74 . Unfortunately, opioids can cause a number of unpleasant side effects. Most common effects include gastrointestinal (nausea, vomiting, constipation) and central nervous system (drowsiness, hypotension and respiratory depression) 89 .
In particular, patients with respiratory or renal impairment (more frequent amongst patients with renal colic) are at increased risk of opioid accumulation and resultant respiratory depression. In certain patients at risk (e.g. elderly and cachectic, other CNS depressants, renal impairment) respiratory depression can be life-threatening. Other opioid side effects include headache, peripheral edema, rash, insomnia and depression 90 . Any patient on opioid medications can develop opioid tolerance and potential for abuse/addiction. This is a significant issue, requiring boxed FDA warning in USA. Tolerance develops with the repeated use of opioids requiring increasing doses to maintain analgesic effects 91 . Rotation of various opioid drugs can be useful in managing tolerance. Meperidine in particular has high risk of developing tolerance 92, 93 . It also carries a risk of serotonin syndrome when combined with certain medications, such as antidepressants 94 . Given these concerns, meperidine use in the US has declined significantly, although it remains in use worldwide.
Tramadol
Tramadol is an atypical opioid analgesic. Its mechanism of action is two-fold, mediated by opioid (mu) and non-opioid (inhibition of monoamine uptake) pathways 95 . Many of the side effects are similar to the opioid drugs, although potential for tolerance and addiction is lower.
There is some evidence of its use for renal colic 96 but further studies are needed. 
Phenazopyridine hydrochloride
Phenazopyridine hydrochloride (Pyridium ® Gemini Laboratories, LLC) is a urinary tract analgesic that exerts a topical analgesic effect on urinary tract mucosa. It is particularly useful for treatment of dysuria, frequency and urgency associated with stone passage or stone surgery. It is also helpful for management of stent symptoms 100 . A typical dose is 200mg tablets three times daily. Common adverse effects include headache, rash, pruritus and GI disturbance. It is contraindicated in renal insufficiency 101 . The drug causes reddish-orange discoloration of urine and may stain fabric and contact lenses. It should not be used for more than a few days as it can mask important symptoms such as infection.
Alpha-blockers
Alpha-1-adrenergic receptor antagonists are used in the medical management of ureteric stones as part of MET (medical expulsion therapy). MET uses drugs to relieve symptoms in uncomplicated renal colic thereby reducing the need for invasive procedures as some stones will pass spontaneously. The alpha-1 adrenergic receptors are predominantly located in the distal ureter 102 . Administration of alpha-1-adrenergic blockers can improve expulsion rates of distal 20 ureteric stones as it allows relaxation of the ureteric muscle 103 , although this is an off-label use.
Alpha-1-adrenergic blockers are also used as an aide in shock wave lithotripsy to improve stonefree rates. Alpha-blockers have also been useful in reducing stent-associated symptoms and pain 104 . Common alpha-1 blockers include terazosin and doxazosin. Usual dosing is outlined in Table 5 . Significant side effects include postural hypotension and syncope (vasodilatation due to the adrenergic blockade effects). Gradual dose titration and administration at night are recommended to reduce these unwelcome effects 105 . Other side effects are asthenia, headache, nasal congestion, nausea, peripheral edema and priapism. Tamsulosin is an alpha-adrenergic antagonist with equal affinity for α1a and α1d receptors 106 .
Since the α1dreceptor is the predominant subtype in the ureter 107 , tamsulosin blockade can improve ureteric relaxation. Tamsulosin has been shown to improve stone passage rates by up to a third in several studies, including by De Sio et al in 2006 108 . It also reduced both the requirement for analgesia and mean stone passage time. However, in 2015 a large randomized trial of 1167 patients (SUSPEND trial) assessing the efficacy of alpha blockers (and calcium channel blockers) vs. placebo failed to demonstrate a significant benefit in stone passage 109 .
Tamsulosin has similar side-effect profile to other alpha-1 blockers but without the need for dose 21 titration, allowing greater convenience for the patients at therapy initiation. Tamsulosin has a slightly higher incidence of ejaculatory dysfunction, due to its affinity for dopaminergic and other central nervous system receptors 110 .
Alfuzosin SR is another α1 selective blocker, with reduced risk of ejaculatory dysfunction 111 . It has also been shown to reduce stent symptoms in a randomized trial 112 .
Corticosteroids
Corticosteroid drugs, such as prednisolone and deflazacort have potent anti-inflammatory effects.
It is thought that these anti-inflammatory effects may improve stone passage by relieving ureteric edema resulting from stone impaction 113 . Several trials had showed faster stone passage with the addition of corticosteroid 114, 115 . However, routine use of corticosteroids is limited by the significant adverse effects. The potent anti-inflammatory actions suppress immune response to intercurrent infections. Corticosteroids can cause salt/water retention, muscle weakness, Cushinoid state, impaired glucose tolerance, impaired wound healing and osteoporosis. Hence these medications are rarely used in managing renal stone disease.
Rowatinex
Rowatinex is an essential oil preparation of terpenic type. Terpenes are known to have diuretic and antibacterial effects as well as spasmolytic and hyperemic effects. Rowatinex was first shown to be effective in a small randomized trial in 1987 116 . In a randomized study of 222 patients in 2011 it was shown to be more effective than placebo in stone clearance after 
Calcium-channel blockers
Nifedipine, an antihypertensive drug, has been the most studied of calcium-channel blockers.
Similar to alpha-1 blockers it is used as part of medical expulsive therapy for selected ureteric stones, although it may be less effective 114 . In the recent SUSPEND trial it was to be no more effective than placebo 109 . Nifedipine reduces contractility of the distal ureter similarly to alphaadrenergic blockers allowing improved stone passage 120 . It is used off-label for medical expulsion therapy. Predictably, Nifedipine can cause dizziness and hypotension and can therefore precipitate or worsen underlying ischemic heart disease. Other side effects include peripheral edema, liver function test derangement and cholestasis or even allergic hepatitis 121 .
Patients can experience flushing, headache, weakness, nausea, muscle cramps and tremor.
Conclusion
There are many different pharmacologic treatments available for the treatment of urinary tract stones. However, each has unique benefits and harms and tailored treatment strategies are necessary in order to appropriately utilize the available options. As we learn more about the mechanisms and etiology of stone formation itself we are hopeful that novel agents continue to be developed to optimally treat patients afflicted with this disease
Expert opinion
This paper provides an up-to-date summary of the literature on medical management of renal stone disease. Key findings include strong evidence for thiazide and potassium citrate use in calcium stones and widespread and effective use of NSAID medications for management of renal colic pain. The subject of MET (medical expulsive therapy) with alpha1 blockers or calcium-channel blockers remains controversial owing to a recent randomized controlled trial of over 1100 patients with no evidence of improved stone passage in the treatment vs. placebo groups 109 . Despite this finding, some are critical of the fact that the study was not specifically powered to detect a difference in distal ureteral stones where the effect of MET is felt to be the strongest. Furthermore, these findings go against the results of previously published metaanalyses 113 and are sure to generate discussion, in particular relating to stone management guidelines. Another area requiring further study is the complex metabolism of citrate, acting as a stone inhibitor while simultaneously raising urinary pH with increased risk of calcium phosphate stone formation. Further studies are required to evaluate this process in more detail. With regard to stone prevention, the only recent new drug used for stone prevention is febuxostat. A trial in 2013 48 has confirmed significantly lowered 24-hour uric acid excretion. However, as yet we have no data on calcium or uric acid stone prevention with this drug. The majority of trials on stone prevention are more than 25 years old. In the meantime our understanding of stone disease has evolved significantly and there may well be multiple new avenues for intervention. For example, a pharmaceutical company is currently trialing a new oxalate-reducing drug 122 that may be of benefit in patients with hyperoxaluria. Perhaps, one day in the future we will have a full armamentarium of effective medical options to prevent various stone types so that surgical treatment is only of historical interest.
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Article highlights
• Renal stones are common and cause significant morbidity
• Thiazide-type diuretics reduce urinary calcium excretion and calcium stone formation 
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